Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma.
作者信息
Kuo Alyce M, Hassoun Hani, Shah Urvi, Gordon Allison, Hollmann Travis J, Landau Heather J, Lezcano Cecilia, Mailankody Sham, Tan Carlyn C, Lesokhin Alexander M, Markova Alina
机构信息
Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
出版信息
Leuk Lymphoma. 2022 Sep;63(9):2233-2237. doi: 10.1080/10428194.2022.2068002. Epub 2022 May 9.
Abstract
摘要
相似文献
1
Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma.度普利尤单抗用于治疗多发性骨髓瘤患者的来那度胺难治性皮疹。
Leuk Lymphoma. 2022 Sep;63(9):2233-2237. doi: 10.1080/10428194.2022.2068002. Epub 2022 May 9.
2
Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma.帕博利珠单抗、来那度胺和地塞米松用于高危多发性骨髓瘤患者自体移植后治疗
Am J Hematol. 2021 Nov 1;96(11):E430-E433. doi: 10.1002/ajh.26333. Epub 2021 Sep 17.
3
Progressive multifocal leukoencephalopathy during treatment with lenalidomide and elotuzumab for multiple myeloma.来那度胺和埃罗妥珠单抗治疗多发性骨髓瘤期间发生的进行性多灶性白质脑病
Leuk Lymphoma. 2020 Sep;61(9):2234-2237. doi: 10.1080/10428194.2020.1765237. Epub 2020 May 18.
4
Impact of prior bortezomib therapy on the incidence of lenalidomide-induced skin rash in multiple myeloma: a propensity score-matched multi-institutional cohort study.硼替佐米预处理对多发性骨髓瘤患者来那度胺诱导皮疹发生率的影响：一项倾向评分匹配的多机构队列研究。
Leuk Lymphoma. 2019 Dec;60(12):2975-2981. doi: 10.1080/10428194.2019.1608531. Epub 2019 May 3.
5
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.帕博利珠单抗联合来那度胺和地塞米松用于初治多发性骨髓瘤患者（KEYNOTE-185）：一项随机、开放标签的3期试验。
Lancet Haematol. 2019 Sep;6(9):e448-e458. doi: 10.1016/S2352-3026(19)30109-7. Epub 2019 Jul 18.
6
Analysis of risk factors for lenalidomide-associated skin rash in patients with multiple myeloma.多发性骨髓瘤患者来那度胺相关性皮疹的危险因素分析。
Leuk Lymphoma. 2021 Jun;62(6):1405-1410. doi: 10.1080/10428194.2021.1876867. Epub 2021 Jan 28.
7
Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen.对于接受含来那度胺联合方案治疗后难治的多发性骨髓瘤患者，用泊马度胺替代来那度胺的疗效和安全性。
Exp Hematol. 2022 Oct;114:54-60. doi: 10.1016/j.exphem.2022.07.303. Epub 2022 Aug 4.
8
Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial.伊沙佐米、卡非佐米、来那度胺和地塞米松治疗新诊断、适合移植的多发性骨髓瘤患者（SKylaRk）：一项单臂、2 期临床试验。
Lancet Haematol. 2024 Jun;11(6):e415-e424. doi: 10.1016/S2352-3026(24)00070-X. Epub 2024 Apr 24.
9
Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan.依洛尤单抗联合来那度胺和地塞米松治疗初诊多发性骨髓瘤：日本一项随机、开放标签、2 期研究。
Int J Hematol. 2020 Jan;111(1):65-74. doi: 10.1007/s12185-019-02757-0. Epub 2019 Nov 7.
10
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.isatuximab联合来那度胺及地塞米松治疗复发/难治性多发性骨髓瘤的1b期研究
Blood. 2017 Jun 22;129(25):3294-3303. doi: 10.1182/blood-2016-09-740787. Epub 2017 May 8.
引用本文的文献
1
Tumors in the setting of dupilumab use: A review of the literature.度普利尤单抗使用情况下的肿瘤：文献综述
World Allergy Organ J. 2024 Dec 11;18(1):101006. doi: 10.1016/j.waojou.2024.101006. eCollection 2025 Jan.
本文引用的文献
1
Simple desensitization protocol for multiple myeloma patients with lenalidomide-induced skin rash: Case series.来那度胺诱导皮疹的多发性骨髓瘤患者的简易脱敏方案：病例系列。
J Clin Pharm Ther. 2021 Dec;46(6):1792-1795. doi: 10.1111/jcpt.13433. Epub 2021 May 7.
2
Immunomodulatory drugs suppress Th1-inducing ability of dendritic cells but enhance Th2-mediated allergic responses.免疫调节药物可抑制树突状细胞诱导Th1的能力，但会增强Th2介导的过敏反应。
Blood Adv. 2020 Aug 11;4(15):3572-3585. doi: 10.1182/bloodadvances.2019001410.
3
Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.多种度普利尤单抗剂量方案在特应性皮炎初始成功治疗后的疗效和安全性：一项随机临床试验。
JAMA Dermatol. 2020 Feb 1;156(2):131-143. doi: 10.1001/jamadermatol.2019.3617.
4
Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center.多发性骨髓瘤患者的来那度胺缓慢脱敏方案：单中心病例系列
Leuk Lymphoma. 2019 Dec;60(13):3199-3203. doi: 10.1080/10428194.2019.1627537. Epub 2019 Jun 13.
5
Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.免疫调节药物（IMiDs）在多发性骨髓瘤中的应用。
Curr Cancer Drug Targets. 2017;17(9):846-857. doi: 10.2174/1568009617666170214104426.
6
Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma.多发性骨髓瘤患者来那度胺相关皮疹的结局与管理
Leuk Lymphoma. 2016 Nov;57(11):2510-5. doi: 10.3109/10428194.2016.1151507. Epub 2016 Mar 4.
7
Practical Management of Lenalidomide-Related Rash.来那度胺相关皮疹的实际管理
Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S64-9. doi: 10.1016/j.clml.2015.02.008.
8
Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.度普利尤单抗可改善中重度特应性皮炎患者的皮肤分子特征。
J Allergy Clin Immunol. 2014 Dec;134(6):1293-1300. doi: 10.1016/j.jaci.2014.10.013.
9
Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.来那度胺脱敏治疗5例多发性骨髓瘤患者的迟发型超敏反应
Br J Haematol. 2014 Oct;167(1):127-31. doi: 10.1111/bjh.12925. Epub 2014 May 14.
10
Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis.癌症患者接受来那度胺治疗时皮疹风险的系统评价和荟萃分析。
Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):424-9. doi: 10.1016/j.clml.2013.03.006. Epub 2013 Jun 13.
Zotero 插件